Sanjivani Paranteral Ltd

Dematerialisation/Rematerialisation status

• Dematerialisation requests received during the quarter were processed and confirmed to the depositories (accepted/rejected).
• Securities dematerialised/rematerialised have been listed on the stock exchanges where the company's earlier securities are listed.
• Physical certificates for dematerialisation were mutilated and cancelled; depository's name substituted as registered owner within timelines.

Sanjivani Paranteral Limited: Trading Window closed from 01st October, 2026 for the purpose of consideration of Un-Audited Financial Result for the Second Quarter and Half Year Ended 30th September, 2026; the Trading Window shall open 48 hours after the Un-Audited Financial Result for the Second Quarter and Half Year Ended 30th September, 2026 become generally available to public.

Sanjivani Paranteral Ltd trading window closed from 01 July 2026 for the Un-Audited Financial Result for the Second Quarter Ended 30 September 2026; shall open 48 hours after the results become generally available to the public.

Use of proceeds details

• Capex of about ₹1.57 crore for machinery, HVAC, and utilities.
• Subsidiary working capital ₹15.64 crore; Sanjivani's share ₹9.38 crore; ₹5.80 crore from warrant proceeds.
• Balance funding to be met from internal accruals.
• Clarification does not modify the object of the issue.
• Disclosure made under Regulation 30 of SEBI LODR.

AGM details

• Date: September 2026; Record date: September 2026; attendance via video conferencing.

Key resolutions

• Adoption of Audited Financial Statements for year ended March 2026; ordinary.
• Re-appointment of retiring directors by rotation; ordinary.

Voting results

• Resolution 1: Passed.
• Resolution 2: Passed.

Dividend

• No dividend declared.

Director changes

• No new director appointments or resignations at AGM.

Auditor appointments

• No auditor changes disclosed.

Material related party transactions

• No material related party transactions disclosed.

Other material approvals

• No other material approvals disclosed.

AGM details

• AGM held on 16 September 2026 at 11:00 A.M. via VC/OAVM.

Key resolutions

• Adopt audited financial statements for year ended 31 March 2026.
• Re-appoint Ashwani Khemka by rotation.

Voting results

• Voting results to be declared on or before 18 September 2026.

Attendance

• Total attendees: 38; shareholders on record: 5,901.
• VC/OAVM attendees: 1 promoter, 37 public.
• Remote e-voting ran 13–15 Sept 2026; post-AGM 15-minute window.

Director / governance

• Ashwani Khemka retires by rotation and is up for re-appointment.

Book closure and AGM details

• Book closure from 10 September 2026 to 16 September 2026, inclusive, for the 32nd AGM.
• Record date fixed as 9 September 2026 to determine voting eligibility.
• AGM will be held on 16 September 2026 at 11:00 IST.
• E-voting period runs 13 September 2026, 09:00 IST to 15 September 2026, 17:00 IST.
• Security affected: equity shares of Sanjivani Paranteral Limited.
• Electronic voting facility available; remote e-voting window provided.

AGM details

• AGM date and time: 16 September 2026 at 11:00 IST.
• Mode: VC/OAVM; venue deemed at the registered office.
• Register of Members/Transfer Books closed 10–16 September 2026 (inclusive).
• Remote e-voting period: 13–15 September 2026.
• Cut-off date for voting eligibility: 9 September 2026.

Ordinary business resolutions

• Adopt Audited Financial Statements for the year ended 31 March 2026.
• Re-appoint Ashwani Khemka, who retires by rotation.

Voting status

• Voting results not disclosed in notice.

Remuneration and terms

• Remuneration proposed for Ashwani Khemka: Rs 12.5 lakh per month.
• Terms remain as approved by members via postal ballot on 20 June 2024.

Annexure: Director details

• Ashwani Khemka, DIN 00337118, born 31-01-1971.
• Date of first appointment: 05-10-1994.
• Shareholding: 36,32,102 shares.
• Experience: 30+ years.
• Remuneration drawn: Rs 12.5 lakh per month.
• Other directorships: SPL Infusion Private Limited; Genesen Labs Limited.

Standalone financials

• Revenue from operations: ₹6,476.39 Lakhs; down 7.61% YoY.
• Total income: ₹6,600.11 Lakhs (Standalone).
• Profit after tax: ₹692.32 Lakhs.
• Earnings per share (Basic): ₹5.67.
• Dividend: Board did not declare any dividend.
• Net cash flows from operating activities: ₹(155.25) Lakhs.

Consolidated financials

• Revenue from operations (Consolidated): ₹6,866.57 Lakhs.
• Total income (Consolidated): ₹6,975.64 Lakhs.
• Profit after tax (Consolidated): ₹669.39 Lakhs.
• Earnings per share (Basic) (Consolidated): ₹5.49.

Capital structure & liquidity

• Warrants converted: 4,02,606; total 6,00,000 converted.
• Equity share capital after conversion: ₹1,228.43 Lakhs.
• Standalone borrowings: ₹667.16 non-current, ₹94.48 current.
• Consolidated borrowings: ₹856.65 non-current, ₹571.39 current.
• Cash & cash equivalents: Standalone ₹115.00 Lakhs; Consolidated ₹124.32 Lakhs.

Strategic growth engines & partnerships

• SPL Infusion Private Limited is 60.87% owned; growth engine.
• Alevia Healthcare S.R.O. (EU) is associate; ₹72.51 Lakhs investment.
• Geographic expansion into Latin America, Africa, Middle East; registrations advancing.
• Pune IV fluids facility commissioned; strengthens growth engine.
• Francophone Africa approvals converting to market access.
• EU nutraceutical foothold via minority investment in Alevia.

Governance & compliance

• Board changes: Basant Shrivastava appointed Independent Director on 11 Sep 2025.
• Board meetings: eight in FY2025-26.
• Audit: Standalone and Consolidated reports unqualified; no fraud reported.
• Related party transactions: arm's length; no material RPTs.
• CSR: CSR obligation ₹7.24 Lakh; spent ₹7.24; set-off ₹7.94.
• Secretarial audit: no qualifications.

Outlook & risks

• FY27 outlook: growth from base, SPL Infusion, and Alevia; diversified exports.
• Risks: tariffs/change in regulation, FX volatility, and supply-chain disruptions.
• Management focus: expand capacity, registrations, and international partnerships.